Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Adoptive cell transfer and oncolytic virus combination therapy

a technology of oncolytic virus and cell transfer, which is applied in the field of conjugated immunotherapy methods for cancer treatment, can solve the problems of increasing healthcare costs, reducing the quality of life of patients, and affecting the survival rate of patients, and achieves the effect of increasing the selectivity of the virus

Inactive Publication Date: 2021-11-04
MCMASTER UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent is about using a special virus to treat cancer. This virus can spread and kill cancer cells. The best type of virus to use is called a rhabdovirus, specifically a VSV or a Maraba rhabdovirus that has been modified to make it more likely to attack cancer cells. Combining this virus with other treatments can make it even more effective.

Problems solved by technology

Cancer and conventional cancer therapeutics currently levy a significant socioeconomic burden in terms of emotional / physical distress, lives lost and increased healthcare costs.
Conventional therapies show some beneficial clinical outcome but have deleterious side effects that often decrease the patient's quality of life [1].
Unfortunately these cells frequently prove ineffective once infiltrated into the tumor and they often exhibit an exhausted and / or dysfunctional phenotype and lack the cytolytic functions necessary to reduce or destroy the tumor due to tumor-induced local immunosuppression [3-5].
Therefore, the immunosuppressive tumor environment remains a significant obstacle blunting the response induced by conventional cancer immunotherapeutics.
Checkpoint inhibitor therapy is reliant on activation of pre-existing TAA specific T cells but in some patients there are not enough pre-existing TAA specific T cells to cause complete tumor regression after therapy induced re-activation [9,10].
However, these dual goals conflict; generating a high dose of T cells requires extensive in vitro expansion that also results in terminal differentiation and replicative senescence of T cells [16].
A method for producing TAA specific central memory T cell culture from PBMC samples has been published [21] but this protocol requires a clinical grade cell sorter, which is labor and resource-intensive, to enrich for the antigen specific cells (also see, U.S. Patent Application Publication No.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Adoptive cell transfer and oncolytic virus combination therapy
  • Adoptive cell transfer and oncolytic virus combination therapy
  • Adoptive cell transfer and oncolytic virus combination therapy

Examples

Experimental program
Comparison scheme
Effect test

example 1

Ex Vivo Culture of TAA-Specific CD8 T Cells Induces a Central Memory Phenotype

[0085]Ex vivo based T cell cultures commonly utilize cytokines that signal through the common gamma chain (IL2Rγ or CD132). Common gamma chain family cytokines include, but are not limited to IL2, IL15, and IL21 [27]. CD132 is mainly expressed on lymphocytes and signaling through this receptor drives proliferation and maturation of CD8+ T cells and other lymphocyte subtypes [27]. IL2 is known to induce rapid proliferation and effector differentiation of CD8 T cells [28-30] whereas IL15 and IL21 are known to drive slower, homeostatic proliferation and bias CD8+ T cells towards a central memory differentiation status [30-32]. Therefore, we utilized IL15, and IL21 supplementation in our ex vivo culture system. In addition, we also employed rapamycin, a commonly used mTOR inhibitor. Regulation of the mTOR pathway has been shown to support survival of T cells and induce memory T cell differentiation in viral va...

example 2

[0087]The Specific Combination of IL21, IL15, and Rapamycin is Required for Guided Differentiation of Antigen-Specific Central Memory CD8+ T Cells with Optimal Anti-Tumor Effect in the Combination Therapy.

[0088]The specific combination of rapamycin, IL15, and IL21 is required for ex vivo culture, expansion and differentiation of antigen-specific central memory CD8+ T cells with optimal anti-tumor effect in the combination therapy described herein. Each, and all, of these components are required to generate such Tcm cells and cells produced in the absence of one or more of these components have sub-optimal T cell expansion and / or reduced anti-tumor effect after in vivo infusion and OV vaccination.

[0089]IL15 is required in the culture protocol to drive CD8+ T cell expansion and central memory differentiation. Cells cultured in the absence of IL15 showed impaired proliferation and a reduced cell yield from the ex vivo culture (IL21 / Rapa in FIG. 2A) compared to cells grown in the full c...

example 3

Transfer of Ex Vivo Cultured Memory T Cells Requires OV Vaccine Boost to Acquire Anti-Tumor Activity

[0092]Central memory CD8 T cells reside in the lymph nodes and remain inactive until stimulated via presentation with their cognate peptide. Upon antigen-specific stimulation, Tcm cells rapidly divide and differentiate into effector cells to generate a robust systemic cytolytic response. The antigen-specific cytolytic function of ex vivo culture generated Tcm cells was tested via adoptive transfer into mice bearing tumors expressing the antigen targeted by the transferred cells followed by activation with an oncolytic virus vaccine expressing the same antigen. We tested three TCR transgenic mouse strains (24H9R, DUC18, and P14 mice) which target antigens expressed on commonly used tumor cell line models representing a true self antigen, a neoantigen and a viral antigen (DCT in B16F10 cells, Erk9M in DUC18 cells, and B16-gp33 cells, respectively). Cultured Tcm cells were adoptively tra...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention describes a method for treating cancer comprising adoptive transfer of tumor antigen specific CD8+ T cells and an oncolytic virus vaccine targeting the same antigen.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application is a continuation of U.S. patent application Ser. No. 16 / 312,897, filed Dec. 21, 2018, which is a national phase entry of PCT / CA2017 / 050772, filed Jun. 23, 2017, which claims the benefit of U.S. Provisional Patent Application Ser. No. 62 / 354,506, filed Jun. 24, 2016, the full disclosures of which are incorporated herein by reference.FIELD OF THE INVENTION[0002]The present invention relates a combinational immunotherapeutic method for treating cancer.BACKGROUND OF THE INVENTION[0003]Cancer and conventional cancer therapeutics currently levy a significant socioeconomic burden in terms of emotional / physical distress, lives lost and increased healthcare costs. Conventional therapies show some beneficial clinical outcome but have deleterious side effects that often decrease the patient's quality of life [1]. There is a need for more effective cancer therapies with fewer and less harmful side effects.[0004]It is well appreciate...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K35/17A61P35/00A61K39/00C12N5/0783
CPCA61K35/17A61P35/00A61K39/0011C12N5/0636A61K2039/5158C12N2501/999A61K2039/545C12N2501/2302C12N2501/2315C12N2501/2321A61K2039/5256A61K35/768A61P37/02A61P35/04C12N2710/24143C12N2760/20243A61K39/001174A61K35/15A61K39/4621A61K2239/31A61K39/464838A61K39/464401A61K39/46433A61K39/4611A61K39/464499A61K2239/38A61K2239/57A61K2300/00
Inventor WAN, YONGHONGWALSH, SCOTTCHEN, LANSALEM, OMARSIMOVIC, BORIS
Owner MCMASTER UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com